Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-272383
Filing Date
2025-11-07
Accepted
2025-11-07 16:16:01
Documents
88
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q gyre-20250930.htm   iXBRL 10-Q 4065169
2 EX-31.1 gyre-ex31_1.htm EX-31.1 19958
3 EX-31.2 gyre-ex31_2.htm EX-31.2 19844
4 EX-32.1 gyre-ex32_1.htm EX-32.1 15836
5 EX-32.2 gyre-ex32_2.htm EX-32.2 15705
  Complete submission text file 0001193125-25-272383.txt   16489586

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT gyre-20250930.xsd EX-101.SCH 1698358
91 EXTRACTED XBRL INSTANCE DOCUMENT gyre-20250930_htm.xml XML 3901861
Mailing Address 12770 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130 (858) 567-7770
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51173 | Film No.: 251462862
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)